More cervical cancer screenings. More lives saved.

According to recent estimates, there will be around 13,000-13,300 new cervical cancer cases and about 4,000 deaths annually in the U.S., with figures for 2026 expected to be similar based on latest available data. More than nine of every 10 cases of cervical cancer are caused by the human papillomavirus (HPV). Yet up to 93% of cervical cancers are preventable.  If more women had access to regular screenings and proactive health care, including the HPV vaccine, fewer women would face this devastating disease.

What’s new in cervical cancer and why it matters

Expanded cervical cancer screening options

The American Cancer Society now recommends self-collected HPV tests as an option for cervical cancer screening. Clinician-collected samples remain the gold standard every five years, but self-collected samples—done at home or in a clinic—are acceptable every three years if negative. This change aims to improve accessibility and compliance for individuals facing barriers to in-office exams. 

Cancer coverage enhancements

Starting in 2026, health plans will be required to cover patient navigation services for breast and cervical cancer screening and follow-up at no cost. These services include scheduling assistance, transportation resources, and education—critical for closing gaps in care among underserved populations. 

Persistent disparities in cervical cancer treatment

Despite these advancements, disparities remain. County-level data show cervical cancer incidence and mortality are 67% and 108% higher in low-resourced U.S. counties compared to high-coverage areas. Black and Hispanic women continue to experience higher mortality rates, and rural areas face 42% higher mortality than urban counties.

Programs like the National Breast and Cervical Cancer Early Detection Program have been reauthorized through 2030 to expand access for uninsured and underinsured women. 

Key cervical cancer stats

• 13,360 new cervical cancer cases and 4,320 deaths projected in the U.S.
• Screening rates still lag behind
• FDA-approved self-collection tools, like the Teal Wand, are expected to drive adoption in 2026

Why this matters

Early detection saves lives—when cervical cancer is found early, the five-year survival rate exceeds 90%. Expanded screening options and navigation services represent critical steps toward reducing preventable deaths and improving equity in care. 

Cervical cancer screening and education can save lives

Improving access to screenings is essential to reducing the number of women diagnosed with cervical cancer. Cancer screening is covered at no cost to the individual under the Affordable Care Act.  Equally important is expanding education about preventing cancer with proactive care. In a study, participants stated “lack of knowledge” was a common reason for not receiving timely screenings for cervical cancer.

Continuing to work with providers to recommend screenings and ensure women understand the recommended guidelines is key. Even if they have received an HPV vaccine, women should still be screened for cervical cancer because the vaccines do not protect against all HPV types that cause cancer.

How Accredo can help support patients with cervical cancer

Awareness of cervical cancer can help women recognize the benefits of regular cancer screenings to prevent it. For those diagnosed with cervical cancer, specialty care is essential. Accredo’s Oncology Therapeutic Resource Center® (TRC) provides personalized support for patients navigating complex therapies. From medication counseling to adherence programs, our dedicated team helps ensure patients stay on track with treatment plans — delivering better outcomes and peace of mind.

This article was created with the assistance of AI tools. It was reviewed, edited, and fact-checked by Evernorth’s editorial team and subject matter experts.

Originally published on 1/24/2023 and updated on 1/14/2026.